Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis

Journal of Cachexia, Sarcopenia and Muscle - Tập 8 Số 6 - Trang 915-925 - 2017
Hiroki Nishikawa1, Hirayuki Enomoto1, Akio Ishii1, Yoshinori Iwata1, Yoshikazu Miyamoto1, Noriko Ishii1, Yukihisa Yuri1, Kunihiro Hasegawa1, Chikage Nakano1, Takashi Nishimura1, Kazunori Yoh1, Nobuhiro Aizawa1, Yoshiyuki Sakai1, Naoto Ikeda1, Tomoyuki Takashima1, Ryo Takata1, Hiroko Iijima1, Shuhei Nishiguchi1
1Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan

Tóm tắt

AbstractBackgroundWe aimed to elucidate the relationship between serum myostatin levels and other markers including skeletal muscle mass and to investigate the influence of serum myostatin levels on survival for patients with liver cirrhosis (LC).MethodsA total of 198 LC subjects were analysed in this study. Myostatin levels were measured using stored sera. We retrospectively investigated the relationship between myostatin level and other markers, and the influence of myostatin level on overall survival (OS). Assessment of skeletal muscle mass was performed using the psoas muscle index (PMI) on computed tomography images at baseline. PMI indicates the sum of bilateral psoas muscle mass calculated by hand tracing at the lumber three level on computed tomography images divided by height squared (cm2/m2). The study cohort was divided into two groups based on the median myostatin value in each gender.ResultsOur study cohort included 108 male and 90 female patients with a median age of 67.5 years. The median (range) myostatin level for male patients was 3419.6 pg/mL (578.4–12897.7 pg/mL), whereas that for female patients was 2662.4 pg/mL (710.4–8782.0 pg/mL) (P = 0.0024). Median (range) serum myostatin level for Child–Pugh A patients (n = 123) was 2726.0 pg/mL (578.4–12667.2 pg/mL), whereas that for Child–Pugh B or C patients (n = 75) was 3615.2 pg/mL (663.3–12897.7 pg/mL) (P = 0.0011). For the entire cohort, the 1‐, 3‐, 5‐, and 7‐year cumulative OS rates were 93.94%, 72.71%, 50.37%, and 38.47%, respectively, in the high‐myostatin group and 96.97%, 83.27%, 73.60%, and 69.95%, respectively, in the low‐myostatin group (P = 0.0001). After excluding hepatocellular carcinoma patients (at baseline) from our analysis (n = 158), the 1‐, 3‐, 5‐, and 7‐year cumulative OS rates were 96.0%, 77.93%, 52.97%, and 39.08%, respectively, in the high‐myostatin group and 96.39%, 87.58%, 77.63%, and 73.24%, respectively, in the low‐myostatin group (P = 0.0005). Higher age (P = 0.0111) and lower PMI (P < 0.0001) were identified as significant predictors of poorer OS in our multivariate analysis, while higher serum myostatin (P = 0.0855) tended to be a significant adverse predictor. In both genders, PMI, serum albumin, prothrombin time, and branched‐chain amino acid to tyrosine ratio showed a significantly inverse correlation with myostatin levels, and serum ammonia levels showed a significantly positive correlation with myostatin levels.ConclusionsHigher serum myostatin levels correlated with muscle mass loss, hyperammonemia, and impaired protein synthesis, as reflected by lower serum albumin levels and lower branched‐chain amino acid to tyrosine ratio levels. High serum myostatin levels were also associated with a reduced OS rate in LC patients.

Từ khóa


Tài liệu tham khảo

10.1016/j.cld.2011.12.009

10.1093/ageing/afu115

10.1111/apt.13549

10.1016/j.nut.2014.07.005

NishikawaH ShirakiM HiramatsuA MoriyaK HinoK NishiguchiS.JSH guidelines for sarcopenia in liver disease (first edition): recommendation from the working group for creation of sarcopenia assessment criteria in the JSH.2016;46(10):951–963.

Santilli V, 2014, Clinical definition of sarcopenia, Clin Cases Miner Bone Metab, 11, 177

Nardelli S, 2016, Sarcopenia is risk factor for development of hepatic encephalopathy after transjugular intrahepatic portosysthemic shunt placement, Clin Gastroenterol Hepatol

10.1007/s13539-012-0069-3

10.3748/wjg.v20.i25.8061

10.1016/j.jhep.2016.07.040

10.1097/01.mco.0000171150.49248.14

10.1016/j.cgh.2011.08.016

10.1093/jn/136.1.295S

10.1002/hep.24412

10.1245/s10434-014-3686-6

10.1016/j.jhep.2015.02.031

10.1002/bjs.9258

10.1007/s00535-014-0964-9

10.1111/hepr.12562

10.1111/hepr.12674

10.1038/387083a0

10.1007/s13539-011-0035-5

10.1213/ANE.0b013e3181eac1c9

10.1073/pnas.1317049110

10.1016/j.jhep.2016.06.004

Dasarathy S, 2016, Cause and management of muscle wasting in chronic liver disease, Curr Opin Gastroenterol, 32, 159

10.4161/auto.27918

10.1530/JOE-15-0533

10.1002/iub.1392

10.1210/jc.2016-1923

10.1016/j.nut.2016.04.003

10.7314/APJCP.2015.16.18.8075

10.2174/1574887110666150916141351

10.1159/000122595

10.1016/j.jhep.2011.05.024

10.1016/j.jhep.2010.07.033

10.1007/s00535-016-1216-y

10.1111/j.1872-034X.2009.00634.x

10.1007/s11894-016-0516-y

10.1016/j.jhep.2011.12.001

10.1159/000327577

10.1002/hep.28852

10.1073/pnas.95.25.14938

10.1200/JCO.2012.45.2722

10.1017/S1751731115000117

10.1002/jcsm.12089